相关实验视频
Updated: May 12, 2026
07:16
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
34.7K
压缩腹膜内冷大气等离子体作为腹膜转移性癌症的新疗法
Tianhao Min1, Bo Zhang2, Kaijie Ren1
1Department of Surgical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Journal of advanced research
|August 27, 2025
概括
通过增强药物分发和透,压缩腹膜内冷大气等离子体 (PICAP) 提供了一种治疗腹膜转移的新方法. 这种创新疗法显著抑制瘤的进展,并显示出预防转移的潜力.
科学领域:
- 癌症学
- 生物医学工程
- 血医学
背景情况:
- 腹膜转移性癌症 (PMC) 由于腹膜- 血屏障和药物分布不均,因此存在治疗挑战.
- 目前的治疗方法如CRS+HIPEC具有较高的并发症率,而PIPAC的透率低于最佳水平.
- 通过反应性氧和物种 (RONS) 进行瘤亡的冷大气等离子体 (CAP) 是有前途的,但其腹膜内应用尚未被探索.
研究的目的:
- 开发压缩性腹膜内冷大气等离子体 (PICAP),将CAP与增压透相结合.
- 克服常规腹腔内疗法的局限性,包括分布和透.
- 评估PICAP对腹膜转移的治疗和预防效果.
主要方法:
- 使用了体外腹膜模型和小鼠腹膜转移模型 (结肠和卵巢癌).
- 在PICAP,PIPAC和HIPEC之间进行了透性和疗效的比较.
- 在小鼠中分析了PICAP治疗后的瘤负担,亡,ROS水平和线粒体功能.
主要成果:
- 与PIPAC和HIPEC相比,PICAP在体外显示出全厚腹膜透,分布更好.
- 在活体中,PICAP显著降低了风,瘤负担,并延长了小鼠模型的存活时间.
- PICAP诱导了线粒体功能障碍,促进了细胞亡和抑制了阿诺基的抗性,预防性治疗实现了100%的存活率.
结论:
- 通过压力增强的RONS透和线粒体亡,PICAP有效地克服腹膜输送障碍.
- 该疗法显著抑制腹膜转移的进展,并显示出预防潜力.
- 通过结合物理和生物化学效应,PICAP为PMC提供了卓越的治疗策略.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...